Dare Bioscience Inc DARE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities
-
Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting
-
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
-
Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil
-
Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand
-
Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth
-
Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series
-
Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society
Trading Information
- Previous Close Price
- $0.74
- Day Range
- $0.71–0.74
- 52-Week Range
- $0.69–3.78
- Bid/Ask
- $0.71 / $0.75
- Shares Outstanding
- 19.67M
- Market Cap
- $14.25M
- Volume/Avg
- 77,209 / 511,920
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.73
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 24
- Website
- https://www.darebioscience.com
Valuation
|
Metric
|
DARE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 7.73 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
DARE
|
|---|---|
Quick Ratio | 0.77 |
Current Ratio | 0.99 |
Interest Coverage | — |
Quick Ratio
DARE
Profitability
|
Metric
|
DARE
|
|---|---|
Return on Assets (Normalized) | −37.52% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −1,079.10% |
Return on Assets
DARE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!C#<<% | LOCK|ZSG> | $127B | |||
| Moderna Inc
MRNA
| LOCK|%#t@<g | LOCK|Yt | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!M#TGj | LOCK|l!!!^ | $81B | |||
| argenx SE ADR
ARGX
| LOCK|db$#wfX | LOCK|@F | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@C%FZ! | LOCK|gH% | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|gYyf#B | LOCK|v%%m | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|P$$Y#$%G | LOCK|shk#m | $27B | |||
| Incyte Corp
INCY
| LOCK|t^&@C? | LOCK|$Xs | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|$!X#Rx# | LOCK|@< | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|nsVBY$ | LOCK|<v | $14B |
United States